[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"glucosamine\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:glucosamine":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100657903","human-absorption-study-of-liposomal-glucosamine-supplements-100657903",false,"NCT07843342","Human Absorption Study of Liposomal Glucosamine Supplements","Effect of Double Nutri® Liposomal Encapsulation Technology on Human Absorption of Glucosamine Supplements","Inclusion Criteria:\n\n* Adults aged ≥18 years, regardless of sex, who are willing to sign the informed consent form and are able to fully comply with all study procedures.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women, or individuals who are unwilling to use a physical method of contraception during the study period, such as condoms or an intrauterine device.\n* Employees of TCI Co., Ltd. and their family members.\n* Individuals who have regularly taken any supplements or medications containing glucosamine or N-acetylglucosamine (N-acetyl-glucosamine) within 14 days prior to study initiation, defined as use for ≥7 consecutive days.\n* Individuals with a history of chronic gastrointestinal disorders, including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), chronic diarrhea, Crohn's disease, celiac disease, bowel control problems\u002Ffecal incontinence, pancreatitis, peptic ulcer disease, colorectal cancer, short bowel syndrome, or ulcerative colitis; a history of epilepsy or seizures; liver or kidney disease; malignancy; endocrine disorders; psychiatric disorders; alcohol or substance abuse; or other significant organic diseases, as determined based on medical history.\n* Individuals with a history of gastrointestinal surgery, organ transplantation, or other major surgery.\n* Individuals who have experienced acute gastroenteritis within 2 weeks prior to study initiation.\n* Individuals with a history of allergy to any ingredient in the investigational products. The investigational products contain shrimp- and soy-derived ingredients.\n* Vegetarians, as the glucosamine used in this study is derived from shrimp.",true,"ALL","18 Years",{"count":20,"type":21},16,"ESTIMATED","INTERVENTIONAL",[24],"NA","The objective of this study is to evaluate the effects of liposomal encapsulation using different ratios of gum arabic and lecithin on the bioavailability of a liquid glucosamine supplement in humans.",[27,28],"Glucosamine","Liposomal Encapsulation",[30,31,32,33],"glucosamine","liposomal","human bioavailability","Double Nutri","RECRUITING","2026-09-21",{"date":37,"type":38},"2026-09-28","ACTUAL",{"date":40,"type":21},"2026-10-21",{"date":42,"type":21},"2027-01-29",{"name":44,"class":45},"TCI Co., Ltd.","INDUSTRY"]